Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific
PR96296
EAST RUTHERFORD, NJ, June 1, 2022, /PRNewswire=KYODO JBN/ --
Cambrex, a leading global contract development and manufacturing organization
(CDMO) providing drug substance, drug product, and analytical services across
the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a
leading provider of environmentally-controlled cGMP stability storage services
for the pharmaceutical, medical device and life science industries,
strategically located in Waterford, Ireland.
"Stability storage and testing is a critical component of drug development and
commercialization of new therapies. Q1 Scientific brings world-class
capabilities to our ever-expanding portfolio of outsourced pharmaceutical
services." said Tom Loewald, CEO, Cambrex. "This acquisition is a natural
extension of our current offerings that will broaden and increase our expertise
in this critical area, as well as our footprint in the European market."
Q1 Scientific's state-of-the-art cGMP facility is ICH validated to meet the
specific storage requirements of any pharmaceutical project, with options from
-80 C storage up to +50 C, with a full range of humidity control. The 20,000
sq. ft. Waterford facility boasts nearly 40 walk-in stability storage chambers,
reach-in freezers and stability units, and ultra-low temperature freezers for
biologic therapies. The company also provides sample management and transport
services.
"We're pleased to join Cambrex as we continue to provide leading stability
storage services to our current customers," said Stephen Delaney, CEO, Q1
Scientific. "With Cambrex's scientific expertise and scale, we'll be able to
accelerate our growth and offer an integrated suite of analytical services,
providing a full range of market-leading solutions for our customers."
Cambrex offers a variety of storage and testing capabilities with walk-in and
reach-in chambers that meet the ICH Q1A requirements. The acquisition will
expand Cambrex's capabilities into the European market.
As pharmaceutical and biopharmaceutical companies continue to seek outsourcing
options for non-core capabilities to reduce their footprint, Q1 Scientific's
stability storage services, combined with Cambrex's industry-leading analytical
services portfolio, provide specialized capabilities of high value to the
industry.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization
(CDMO) that provides drug substance, drug product, and analytical services
across the entire drug lifecycle. With over 40 years of experience and a
growing team of over 2,200 experts servicing global clients from North America
and Europe, Cambrex is a trusted partner in branded and generic markets for API
and finished dosage form development and manufacturing.
Cambrex offers a range of specialized drug substance technologies and
capabilities, including biocatalysis, continuous flow, controlled substances,
solid-state science, material characterization, and highly potent APIs. In
addition, Cambrex can support conventional dosage forms, including oral solids,
semi-solids, and liquids, and has the expertise to manufacture specialty dosage
forms such as modified-release, fixed-dose combination, pediatric, bi-layer
tablets, stick packs, topicals, controlled substances, sterile, and non-sterile
ointments.
About Q1 Scientific
Q1 Scientific was founded in Waterford, Ireland in 2013 by Louise Grubb, and
offers environmentally controlled stability storage services to the
pharmaceutical, medical device and life sciences industries at their 20,000 sq
ft. cGMP facility. As the first company in the sector to establish in Ireland,
Q1 Scientific is revolutionizing the way pharmaceutical companies store their
products, helping to improve the speed it takes for new drugs to reach the
marketplace along with saving companies the expense of building and monitoring
their own storage chambers.
For more information, visit www.cambrex.com or www.q1scientific.com
Contact:
Jennifer Therrien
Jennifer.therrien@cambrex.com
Photo: https://mma.prnewswire.com/media/1830432/Cambrex_Q1_Scientific.jpg
Logo: https://mma.prnewswire.com/media/1723116/Cambrex_40_Years_Logo.jpg
Logo: https://mma.prnewswire.com/media/1830431/Q1_Scientific_Cambrex_Logo.jpg
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。